Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-03-05 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
关于2016年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use and management of funds raised by the company through a public offering, including specifics on the amount raised, usage, storage, investment projects, and compliance with regulatory requirements. It includes financial figures, project progress, and explanations of fund usage and surplus. The document is titled as a "专项报告" (special report) on the storage and use of raised funds for the year 2016. This type of document corresponds to a Capital/Financing Update (CAP) as it focuses on fundraising proceeds and their deployment rather than a full annual or interim financial report. It is not an announcement of a report publication, nor a certification or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2017-03-05 Chinese
第三届监事会第十四次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Quantum Hi-Tech (China) Biological Co., Ltd. It details the approval of various reports and proposals related to the 2016 fiscal year, including the Supervisory Board Work Report, the 2016 Financial Final Report, the 2016 Annual Report and Summary, the 2016 Internal Control Self-Evaluation Report, and other financial and operational proposals. The document states that these reports are available on the designated disclosure website and that the resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or detailed financial statements but rather the Supervisory Board's resolutions and opinions on these reports. It is a formal announcement of the Supervisory Board meeting decisions rather than the full annual report or financial statements. Therefore, it fits best under Regulatory Filings (RNS) as a formal regulatory announcement of meeting resolutions and report approvals, not the reports themselves.
2017-03-05 Chinese
关于2017年度日常关联交易预计公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the expected related party transactions for the fiscal year 2017 by Quantum Hi-Tech (China) Biological Co., Ltd. It details the nature, amounts, counterparties, and rationale for these related party transactions. The document includes information about the company's board meeting approval and independent directors' opinions on these transactions. It is a regulatory announcement about anticipated related party transactions rather than a full financial report or audit. The document length is 3309 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication of financial statements or comprehensive financial data. Therefore, this document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2017-03-05 Chinese
2016年度募集资金存放与使用情况的专项鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项鉴证报告" (Special Verification Report) on the storage and use of raised funds for the year 2016 by 量子高科 (China) Biological Co., Ltd. It includes detailed financial data on the amount of funds raised, their usage, storage, management, and investment projects related to the raised funds. The document references compliance with Shenzhen Stock Exchange regulations on the management and disclosure of raised funds. It is a standalone audit-type report focusing specifically on the verification of the raised funds' storage and usage, rather than a full annual or interim financial report. It is not an announcement or a brief summary but a detailed verification report by an accounting firm. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. FY 2016
2017-03-05 Chinese
关于举办2016年度网上业绩说明会的通知
Investor Presentation Classification · 95% confidence The document is a notice about the holding of the 2016 annual performance explanation meeting (业绩说明会), scheduled for March 15, 2017. It invites investors to participate in an online presentation with company executives. The document is short (490 characters) and serves as an announcement of the event rather than the event content or transcript itself. It does not contain financial data or detailed report content. Therefore, it fits the category of Investor Presentation (IP) as it relates to a presentation for investors focusing on financials and company performance.
2017-03-05 Chinese
关于重大资产重组停牌进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the progress of a major asset restructuring and the related stock trading suspension. It details the timeline of suspension, disclosures made, board meeting decisions, and plans for a shareholder meeting to discuss the restructuring. The document does not contain financial statements or detailed financial data but is an update on the status of a significant corporate transaction and related regulatory compliance. This fits the category of a Capital/Financing Update (CAP), as it concerns fundraising or capital structure changes through a major asset reorganization. The document length is short (1156 characters), and it is not merely announcing the publication of a report but providing substantive progress updates. Therefore, the appropriate classification is CAP with high confidence.
2017-02-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.